Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. (Q38023942)

From Wikidata

Jump to navigation Jump to search

scientific article published on 05 July 2012

Language	Label	Description	Also known as
English	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.	scientific article published on 05 July 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Asuka Nakata

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

5 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Expert Opinion on Therapeutic Targets

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

771-781

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR and erbB2 mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Somatic mutations of the ERBB4 kinase domain in human cancers

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Status of PI3K inhibition and biomarker development in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

EGFR exon 20 insertion mutation in Japanese lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Exploring the cancer genome in the era of next-generation sequencing

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697155

21 January 2018

Identifiers

10.1517/14728222.2012.697155

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22762482%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38023942&oldid=1511463627"